A pharma industry group is urging the U.S. Food and Drug Administration (FDA) to block what it calls a “dangerous” Super Bowl ad from the digital healthcare company Hims & Hers (HIMS), promoting an off-brand version of Ozempic.
A pharma industry group is urging the U.S. Food and Drug Administration (FDA) to block what it calls a “dangerous” Super Bowl ad from the digital healthcare company Hims & Hers (HIMS), promoting an off-brand version of Ozempic.Read more…